Good Distribution Practice (GDP) refers to the entirety of the requirements that ensure medicinal products are stored, transported and handled along the entire supply chain in a manner that preserves their quality, integrity and efficacy. GDP applies to all stages of distribution – from the manufacturer through the wholesaler to the pharmacy or the investigational site. In the EU, GDP is binding under the guideline of the European Commission (2013/C 343/01) and forms the pharmaceutical counterpart to GMP on the manufacturing side. GDP is particularly relevant for clinical trials because investigational medicinal products often have to be distributed across multiple national borders and under specific storage conditions. Deficiencies in distribution can jeopardise the integrity of the investigational substance and call into question the usability of entire data packages.
Regulatory basis in the EU
The EU GDP guideline is based on Article 84 of Directive 2001/83/EC and applies to all persons and undertakings distributing medicinal products at wholesale level in the EU. It was fundamentally revised in 2013 to reflect modern requirements for supply chain security, anti-counterfeiting measures and temperature management. In Germany, GDP is implemented nationally through the Arzneimittelhandelsverordnung (Medicinal Products Trading Regulation) and guidance from the Federal Institute for Drugs and Medical Devices.
Wholesale distributors require an authorisation from the competent authority and are subject to regular inspections by national authorities. For investigational medicinal products in clinical trials, the GMP requirements under Annex 13 of the EU GMP Guide and Regulation (EU) 536/2014 additionally apply. Compliance with GDP requirements is therefore not an optional standard but a statutory obligation with direct consequences for non-compliance – up to and including suspension of the wholesale distribution authorisation. Inspection findings are recorded in the EU database for wholesale distribution authorisations and are accessible to other authorities and clients, which further increases the reputational risk of non-compliance.
Key requirements at a glance
A functioning quality management system is the foundation of any GDP-compliant operation. It comprises written procedures for all relevant processes, a training and qualification programme for personnel, and a structured system for deviations, changes and corrective actions. The responsible person, referred to in EU terminology as the Responsible Person, bears overall responsibility for GDP compliance within the organisation and must be notified to the authorities and be professionally qualified.
Storage and transport are the core operational areas. Temperature conditions, light protection, humidity and access controls must be regulated in a product-specific and documented manner. For temperature-sensitive products such as biologics or cold-chain medicinal products, validated transport containers, continuous temperature monitoring and clearly defined processes for managing temperature excursions are mandatory. Every deviation must be documented, assessed and, where applicable, submitted to the manufacturer for a quality decision. Without complete temperature records, product quality cannot be demonstrated in the event of a dispute, which is regularly classed as a Critical Finding during inspections.
GDP in clinical trials
In clinical trials, GDP is closely linked to Drug Accountability and the GMP-compliant provision of investigational medicinal products. The sponsor bears overall responsibility for the GDP-compliant supply chain from the manufacturer to the investigational site. This responsibility can be delegated to qualified logistics partners or CROs, but the sponsor remains legally responsible. Typical GDP-relevant processes in trials include the release and dispatch of investigational medicinal products by a qualified pharmacy or a contract manufacturer, the qualification of couriers and logistics partners, and complete documentation of all product movements.
Particular care is required for cross-border transport in multinational trials. Import and export restrictions, customs regulations and country-specific requirements for accompanying documents must be fully clarified before the first shipment. Customs delays or missing import licences can lead to supply shortages at investigational sites and jeopardise the entire trial timeline. Early planning together with the Regulatory Affairs team and experienced logistics partners is therefore essential. Lead times for import authorisations, national approval requirements for the investigational medicinal product, and the availability of GDP-certified storage facilities in the destination country should already be assessed during the trial planning phase.
Relevance for sponsors and CROs
Full-service CROs such as mediconomics support sponsors in qualifying GDP-compliant suppliers and logistics partners, preparing Quality Agreements, and preparing for regulatory inspections. Incomplete GDP documentation is among the frequent findings during inspections by the EMA and national authorities. Deficiencies can lead to the rejection of investigational medicinal product batches, the suspension of deliveries, or – in the most serious case – the invalidation of trial data if product integrity cannot be adequately demonstrated. A robust GDP system therefore protects not only patients but also the usability of the entire trial dataset.
Frequently Asked Questions (FAQ)
Does GDP also apply to investigational medicinal products in clinical trials?
Yes. Investigational medicinal products are subject to both GMP requirements (in particular Annex 13 of the EU GMP Guide) and GDP requirements for all distribution steps from the manufacturer to the investigational site. The precise delineation between GMP and GDP responsibilities must be assessed on a case-by-case basis and set out in the Quality Agreement between the sponsor and its service providers.
Who is the Responsible Person in the GDP context?
The Responsible Person is a named, qualified professional within the wholesale distribution organisation who is responsible for GDP compliance. They must be notified to the competent authority and must demonstrably possess the required training and professional experience. The authority must be informed without delay of any change of Responsible Person.
What happens in the event of a temperature excursion during transport?
A temperature excursion must be documented immediately and assessed by the manufacturer’s or sponsor’s quality assurance function. Based on this assessment, the responsible party decides whether the affected batch can continue to be used or must be quarantined and destroyed. Complete documentation of the deviation, the assessment and the measures taken must be available for audits and inspections.